These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 8319175)

  • 1. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.
    Morra E; Lazzarino M; Brusamolino E; Pagnucco G; Castagnola C; Bernasconi P; Orlandi E; Corso A; Santagostino A; Bernasconi C
    Cancer; 1993 Jul; 72(2):439-45. PubMed ID: 8319175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
    J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C).
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Regazzi Bonora M; Pagnucco G; Orlandi E; Bernasconi P; Canevari A; Rondanelli R
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():101-3. PubMed ID: 2713552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
    Castagnola C; Nozza A; Corso A; Bernasconi C
    Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma.
    Moser AM; Adamson PC; Gillespie AJ; Poplack DG; Balis FM
    Cancer; 1999 Jan; 85(2):511-6. PubMed ID: 10023723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
    Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
    J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
    Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
    J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma.
    Willemze R; Peters WG; Colly LP
    Eur J Haematol; 1988 Nov; 41(5):489-95. PubMed ID: 3208871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.
    Ellison RR; Mick R; Cuttner J; Schiffer CA; Silver RT; Henderson ES; Woliver T; Royston I; Davey FR; Glicksman AS
    J Clin Oncol; 1991 Nov; 9(11):2002-15. PubMed ID: 1941059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.
    Laver JH; Barredo JC; Amylon M; Schwenn M; Kurtzberg J; Camitta BM; Pullen J; Link MP; Borowitz M; Ravindranath Y; Murphy SB; Shuster J
    Leukemia; 2000 Mar; 14(3):369-73. PubMed ID: 10720128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Lee EJ; Petroni GR; Schiffer CA; Freter CE; Johnson JL; Barcos M; Frizzera G; Bloomfield CD; Peterson BA
    J Clin Oncol; 2001 Oct; 19(20):4014-22. PubMed ID: 11600602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoblastic lymphoma in adult patients: clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia.
    Bernasconi C; Brusamolino E; Lazzarino M; Morra E; Pagnucco G; Orlandi E
    Ann Oncol; 1990; 1(2):141-6. PubMed ID: 2078494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences].
    Fukushima T; Ueda T; Kamiya K; Yoshida W; Tsutani H; Uchida M; Nakamura T; Kagawa D; Domae N
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):126-31. PubMed ID: 2324584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy.
    Whelan JS; Davis CL; Rohatiner AZ; Leahy M; MacCallum PK; Gupta RK; Matthews J; Norton AJ; Amess JA; Lister TA
    Hematol Oncol; 1992; 10(2):87-94. PubMed ID: 1592366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.